We are Healthy
World

Efruxifermin Shows Long-Term Benefits for MASH Patients

Adults with MASH showed sustained fibrosis improvements after 96 weeks of weekly efruxifermin injections.

Updated on Oct. 20, 2026 in Diabetes

Isometric editorial illustration showing stylized geometric structures representing liver cell tissue stability and systemic cellular health.
New clinical trial data indicates that the experimental drug efruxifermin sustained liver fibrosis improvements in MASH patients over 96 weeks of treatment. AI Illustration. Upload story photo >

Live Poll

Is now a good time to consider new drug treatments for chronic liver conditions?

Long-term data from the HARMONY and SYMMETRY trials show that the experimental drug efruxifermin can improve fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH). Patients receiving a 50 mg weekly dose maintained significant liver health improvements through 96 weeks of treatment.

Why it matters

MASH is a progressive liver condition that can lead to advanced scarring or cirrhosis, and these findings suggest that sustained treatment may help patients manage fibrosis over the long term. This evidence supports the ongoing evaluation of the drug as researchers move through clinical development phases.

These Phase 2 results from the HARMONY and SYMMETRY trials assessed liver biopsy outcomes in 307 total participants over 96 weeks. While 75% of patients in the 50 mg group achieved a fibrosis response in HARMONY compared to 24% for placebo, the Phase 3 trials are still ongoing.

The details

Participants in the study received subcutaneous injections of efruxifermin once a week to manage liver scarring and metabolic dysfunction. The data shows that 92% of patients who achieved a response by week 24 maintained those results through the end of the 96-week period, alongside improvements in liver stiffness measurements. Common adverse events reported throughout the study included administration site reactions and gastrointestinal symptoms.

Timeline

  1. Baseline: Initial liver biopsies were performed.

  2. Week 24: Liver biopsies were conducted for the HARMONY trial participants.

  3. Week 36: Liver biopsies were conducted for the SYMMETRY trial participants.

  4. Week 96: Final biopsies were assessed to determine long-term treatment response.

  5. October 20, 2026: Results were presented at the ACG meeting in Nashville.

Health Landscape

Treating metabolic dysfunction-associated steatohepatitis remains a significant challenge, with few established therapies available for advanced fibrosis. This study provides a vital bridge toward the ongoing Phase 3 trials of efruxifermin, which aim to confirm if these long-term results translate to broader clinical benefit.

If you are managing MASH with advanced fibrosis, these results offer insight into how long-term consistency in clinical trials impacts liver scarring. It is worth discussing with your doctor how these findings fit into the current standard of care and whether you may be a candidate for future clinical research trials.

The takeaway

The data indicates that a 50 mg weekly dose of efruxifermin can provide sustained improvements in liver fibrosis for patients with MASH. Patients should continue working with a hepatologist to monitor liver stiffness and discuss the evolving landscape of available clinical research options.

Further reading

For more on managing metabolic conditions and liver health, see our latest coverage on Diabetes.

Live Poll

Is now a good time to consider new drug treatments for chronic liver conditions?